Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.67 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.64 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 2/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9946046 | 0.86 | MAOB (0.65) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL4304772 | 0.86 | MAOB (0.63) | MAOBNR4A2PARP10MAOAENPP2 | |
| SCHEMBL3625818 | 0.85 | MAOB (0.73) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL27521276 | 0.84 | MAOB (0.77) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL2563261 | 0.83 | MAOB (0.65) | MAOBNR4A2MAOAENPP2 | |
| SCHEMBL31580896 | 0.83 | MAOB (0.65) | MAOBNR4A2MAOAENPP2 | |
| SCHEMBL177403 | 0.83 | MAOB (0.62) | MAOBMAOAENPP2 | |
| SCHEMBL29954055 | 0.83 | MAOB (0.62) | MAOBMAOAENPP2 | |
| SCHEMBL4228288 | 0.82 | MAOB (0.73) | MAOBNR4A2PARP10MAOA | |
| SCHEMBL29817726 | 0.82 | MAOB (0.73) | MAOBNR4A2PARP10MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| CN-108368107-B | Fused heterocyclic compounds as S1P modulators | 艾伯维公司 | 2021-11-26 | — | — | CN | disclosed |
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-02-11 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-3107908-B1 | PYRIDIN-3-YL ACETIC ACID DERIVATIVES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2019-03-27 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| EP-3341369-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-3147285-A2 | PURINONE COMPOUNDS AS KINASE INHIBITORS | Pharmacyclics, Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| WO-2017036978-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | ABBVIE INC. (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20140378446-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| EP-2809672-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | Pharmacyclics, Inc. (US) | 2014-12-10 | — | — | EP | disclosed |
| EP-2435436-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| WO-2013116382-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-08-08 | — | — | WO | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| US-8354422-B2 | Pyrimidine inhibitors of kinase activity | ABBOTT LABORATORIES INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | MAOB 780/4885NR4A2 754/4885PARP10 609/4885 |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | IGF1R, CDK2, TK1 | MAOB 1887/4885NR4A2 1879/4885PARP10 456/4885 |
| US-20140378446-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, BCL9 | MAOB 2103/4885NR4A2 3241/4885PARP10 221/4885 |
| US-10556907-B2 | Fused heterocyclic compounds as S1P modulators | S1PR1, S1PR2, S1PR3 | MAOB 3377/4885NR4A2 680/4885PARP10 545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.